Multi-omics Analysis Reveals the Protection of a Quadruple Probiotic Mixture in Experimental Autoimmune Hepatitis

Autoimmune hepatitis (AIH) is a chronic liver disease where the immune system attacks the liver, and current treatments often fall short or cause significant side effects. This study tested whether a four-strain probiotic mixture — containing Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, and Bacillus cereus — could reduce liver damage in a mouse model of AIH. Researchers used a multi-omics approach, combining gut microbiome sequencing, metabolomics, and transcriptomics, to understand not just whether the probiotics worked, but how. The probiotic mixture significantly reduced markers of liver injury and inflammation, and partially reversed the gut microbial imbalance (dysbiosis) characteristic of AIH. A key mechanism appeared to involve restoration of the intestinal barrier — leaky gut allows bacterial endotoxins like lipopolysaccharide (LPS) to enter the bloodstream and fuel liver inflammation. The probiotics also shifted hepatic metabolism (particularly the citrate cycle and tryptophan pathways) and dampened pro-inflammatory immune signaling via NF-κB and NOD-like receptor pathways. The findings position this probiotic combination as a promising adjunctive therapy for AIH, though further human trials are needed to confirm these effects.

• Probiotic-quad treatment significantly reduced serum liver enzyme levels and ameliorated hepatic inflammatory infiltration and histopathological damage in a chronic AIH murine model.
• Metagenomic sequencing showed partial reversal of gut dysbiosis in AIH mice following Probiotic-quad administration, alongside restoration of intestinal epithelial barrier integrity and a reduction in serum lipopolysaccharide (LPS) levels.
• Untargeted metabolomics and transcriptomics identified alterations in hepatic citrate cycle and tryptophan metabolism, and reduced activation of NF-κB and NOD-like receptor (NLR) signaling pathways as mechanistic correlates of the probiotic's protective effect.

This was a preclinical experimental study using a well-established chronic AIH murine model. Mice received the quadruple probiotic mixture (Probiotic-quad: Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, Bacillus cereus) and were assessed for liver injury, gut microbiota composition (metagenomic sequencing), intestinal barrier function, serum LPS, hepatic metabolome (untargeted metabolomics), and hepatic gene expression (transcriptomics). The multi-omics integration approach allowed mechanistic pathway mapping across gut-liver axis compartments. Specific sample sizes, dosing regimens, and treatment durations are not reported in the abstract.

This study is entirely preclinical (murine model), and the translation of both efficacy and mechanistic findings to human AIH remains unestablished. The specific strains and doses used in this quadruple mixture may not reflect commercially available formulations, and the relative contribution of each individual strain to the observed effects is not disaggregated. Causality between the metabolomic/transcriptomic changes and clinical improvement cannot be fully established from correlational multi-omics data alone. A next critical experiment would be a randomized controlled trial in AIH patients (ideally stratified by gut microbiome baseline) or at minimum a germ-free mouse colonization study to confirm mechanistic directionality.

This study extends the gut-liver axis mechanistic framework shared with [§127], which similarly examines how gut microbiota-targeted interventions alleviate hepatic inflammation via microbiome remodeling and metabolic reprogramming, though [§127] addresses alcohol-induced injury rather than autoimmune etiology. It parallels [§120], which investigates how specific bacterial interventions modulate gut microbiota and NF-κB signaling to resolve chronic inflammatory disease, reinforcing NF-κB suppression as a convergent mechanism across probiotic studies in this corpus. The intestinal barrier restoration and LPS-reduction mechanism described here also parallels findings in [§145], where nanoparticle-delivered polyphenols similarly improved gut barrier integrity and microbiota composition in inflammatory liver disease through multi-omics-confirmed pathways. The broader relevance of probiotic mixtures containing overlapping strains for immune-mediated conditions is further contextualized by [§156], which examines an Akkermansia-centered intervention for inflammatory skin disease through gut microbiota modulation, illustrating how compositionally similar probiotic strategies are being evaluated across divergent inflammatory phenotypes.

• Yajieshaba extract improves alcohol‑induced liver injury by regulating hepatic lipid metabolism and gut microbiota
  Both study gut microbiota-targeted interventions for liver disease via the gut-liver axis, but target different etiologies (alcoholic vs. autoimmune), making direct mechanistic comparison informative for understanding disease-specificity of microbiome effects.
• Eubacterium rectale Mitigates Inflammatory Bowel Disease via Modulation of Glutamine Metabolism Through the GLS2 and NF-κB Pathway
  Both identify NF-κB signaling suppression and gut microbiota modulation as central mechanisms of probiotic or bacterial interventions in chronic inflammatory disease, enabling mechanistic cross-validation despite different target organs.
• Green tea polyphenol-iron oxide chitosan nanoparticles modulate gut microbiota and regulate metabolic pathways
  Both use multi-omics approaches to characterize gut microbiota and metabolic pathway changes in inflammatory liver disease models, allowing comparison of probiotic versus polyphenol-nanoparticle strategies for gut-liver axis modulation.
• Sichuan dark tea with a medicine-food-homology formula synergistically alleviates alcohol-associated gut microbiota disturbance, liver steatosis and death in mice
  Both investigate microbiota-modulating interventions for liver disease using overlapping omics methods, but compare a defined probiotic mixture against a traditional medicine formula, offering contrast in intervention specificity and mechanistic resolution.
• Editorial: The role of gut microbiota in immune-related inflammatory diseases
  This editorial provides direct conceptual framing for the role of gut microbiota in immune-related inflammatory diseases, situating the AIH probiotic findings within the broader field of microbiota-immunity research reviewed in this corpus.